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Background: Mesoporous silica nanoparticles (MSNs) have several attractive properties as a drug delivery system,
such as ordered porous structure, large surface area, controllable particle size as well as interior and exterior
dual-functional surfaces. The purpose of this study was to develop novel lactosaminated mesoporous silica
nanoparticles (Lac-MSNs) for asialoglycoprotein receptor (ASGPR) targeted anticancer drug delivery.
Results: Lac-MSNs with an average diameter of approximately 100 nm were prepared by conjugation of
lactose with 3-aminopropyl triethoxysilane modified MSNs. Characterization of Lac-MSNs indicated a huge
Brunauer-Emmett-Teller (BET) surface area (1012 m2/g), highly ordered 2D hexagonal symmetry, an unique
mesoporous structure with average pore size of 3.7 nm. The confocal microscopy and flow cytometric analysis
illustrated Lac-MSNs were effectively endocytosed by ASGPR-positive hepatoma cell lines, HepG2 and SMMC7721.
In contrast, non-selective endocytosis of Lac-MSNs was found in ASGPR-negative NIH 3T3 cells. The cellular uptake
study showed the internalization process was energy-consuming and predominated by clathrin-mediated pathway.
Model drug docetaxel (DTX) was loaded in the mesopores of Lac-MSNs by wetness impregnation method. In vitro
cytotoxicity assay showed that DTX transported by Lac-MSNs effectively inhibited the growth of HepG2 and
SMMC7721 cells in a time- and concentration- dependent manner.
Conclusions: These results demonstrated that Lac-MSNs could be a promising inorganic carrier system for targeted
intracellular anti-cancer drug delivery.
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In recent years, more than ten million people per year
worldwide have suffered from cancers, and cancer is one
of the deadliest killers to human being [1]. Currently, sys-
temic chemotherapy is the indispensable treatment for
malignant tumors. However, many anticancer drugs have
severe toxic side effects due to their unspecific actions on
normal cells and tissues [2]. Therefore, development of an
effective cancer targeting drug delivery system is extremely
necessary for improving the drug efficacy to cancer cells,
reducing toxic side effects systematically, and prolonging
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unless otherwise stated.With recent advances in nanotechnology research,
nanocarries have shown great potential to improve the
therapeutic efficacy while minimize the side effects, espe-
cially for highly toxic anticancer drugs [3,4]. It is known
that the vascular architecture and the lymphatic system in
tumors are impaired and may allow the permeation of
macromolecules. So, passive targeting of nanocarriers to
these abnormal tumors may be partially achieved with the
enhanced permeability and retention (EPR) effect [5,6],
leaving the surrounding healthy tissues barely touched. It
is expected that the application of nanotechnology would
be beneficial to millions of cancer patients with more effi-
cient, safe, and affordable treatment.
Though the common organic nanocarriers including
polymeric micelles [7], nanocapsules [8], polymer nanopar-
ticles [9], and liposomes [10] have been extensively studied,
their physicochemical instability and undesirable drughis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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contrast, inorganic silicate (SiO2) carriers possess many ad-
vantages, such as great physicochemical and biochemical
stabilities, good biocompatibility, and excellent degradabil-
ity [11]. Recently, silica nanoparticles in the form of Cornell
dots (C dots) received FDA’s approval for stage I human
clinical trial [12-14], representing an important step to-
wards clinical acceptance of silica-based nanoparticles.
Among silica-based nanomaterials, mesoporous silica
nanoparticles (MSNs) have attracted great attention due
to their unique properties, including highly regular meso-
porous structure, tunable pore size (2–10 nm), huge sur-
face area (>700 m2/g), large pore volume (>1 cm3/g),
excellent endocytotic behavior, and good biocompatibility
both in vitro and in vivo [15-17]. Several chemotherapeu-
tic agents have been successfully delivered by using MSNs
as cancer cell-specific delivery vehicles [18-20]. More im-
portantly, the external surface of MSNs can be modified
with tumor-recognition molecules to increase the active
targetability through the receptor-mediated endocytosis.
Several well-known targeting molecules, such as folate
[21], mannose [22], hyaluronic acid [23], arginine-glycine-
aspartate (RGD) [24], and lactobionic acid [25] have been
conjugated to MSNs successfully, resulting in significantly
enhanced antitumor efficiency.
Among various targeting ligands, lactose, a glucosyl-
galactose disaccharide, shows great promise as a tumor-
homing agent, because it has a specific interaction with
the asialoglycoprotein receptor (ASGPR) which is a well-
characterized molecular target expressed on the cell surface
of hepatocytes and hepatomas. ASGPR can actively
internalize the bound galactose or galactose-derived com-
plexes via receptor-mediated endocytosis [26,27]. Moreover,
due to its low cost, nonimmunogenicity, high stability, and
ease for modification, lactose has been recognized as a
promising candidate for hepatocellular carcinoma targeting
agent. Many researchers have applied lactose to target drug
delivery system [28-30]. However, to the best of our know-
ledge, there is no report on combining lactose with MSNs
to construct a drug delivery system for hepatocellular car-
cinoma targeting.
So, in this study, the targeting property of lactose was
integrated with the excellent drug delivery and endocytotic
behaviors of MSNs to build a novel drug delivery system,
which was expected to possess not only a passive targeting
capability via EPR effect but also an active targeting char-
acter (Figure 1). Moreover, the internalization mechanism
of MSNs by hepatoma cells was investigated to thoroughly
understand the efficiency of the lactosaminated MSNs.
Results and discussion
Preparation and characterization of MSNs and Lac-MSNs
MSNs were synthesized by the sol–gel method using
surfactant as the template. The as-synthesized MSNsprior to removing the template were firstly functional-
ized with NH2-silane on the outer surface, while leaving
the inner pores available for drug loading. After conjuga-
tion of MSNs with lactose, the template was removed by
refluxing the product in acidic ethanol. In addition, fluor-
escein isothiocyanate (FITC) as a fluorescent probe was
encapsulated in the Lac-MSNs through co-condensation
in order to monitor the interaction between the nanoparti-
cles and the cells [31].
The scanning electron microscopy (SEM) and trans-
mission electron microscopy (TEM) images (Figure 2)
showed that both MSNs and Lac-MSNs were roughly
spherical in shape and uniform in diameter of approxi-
mately 100 nm. The mesoporous structure of MSNs was
revealed in details by TEM, as the clearly observed
bright and dark domains (Figure 2C and D), corre-
sponding to the pores and the silica walls respectively,
confirmed the hexagonal arrays of nanochannels. It is
known the particle size of nanoparticles plays an im-
portant role on pharmacokinetics. Nanoparticles with
particle size smaller than 200 nm can generally increase
accumulation of anticancer drug in tumor via EPR ef-
fect [5]. Though the particle size of Lac-MSNs was mea-
sured as approximately 100 nm based on the TEM
images, this only represented the size of inorganic silica
core, while the organic NH2-silane coating was trans-
parent under TEM observation [32]. Therefore, dy-
namic light scattering (DLS) was employed to measure
the overall size of Lac-MSNs as 170 nm approximately.
The difference in particle size obtained from TEM and
DLS measurements confirmed the successful deposition
of a NH2-silane layer on the nanoparticle surface. These
silane-layer coated, well-dispersed, small nanoparticles
should be favorable for passive tumor targeting and cel-
lular uptake [32,33].
The mesostructure ordering of nanoparticles was ana-
lyzed by X-ray diffraction (XRD) patterns (Figure 3),
where three distinct diffraction peaks indexed at (100),
(110), and (200) revealed that both MSNs and Lac-MSNs
had a highly ordered 2D hexagonal (P6mm) symmetry
[34]. Nitrogen adsorption-desorption measurements are
usually employed to obtain precise information about the
structure of porous materials. As shown in Figure 4, both
MSNs and Lac-MSNs exhibited the classical type-IV iso-
therms with H1-type hysteresis. According to the Inter-
national Union of Pure and Applied Chemistry (IUPAC)
classification [35], this suggests that both MSNs and
Lac-MSNs have uniform mesoporous channels and
relatively narrow pore size distribution (the insert of
Figure 4), in consistence with the TEM images and the
results of XRD. Moreover, the mean surface area, pore
volume, and pore size of MSNs and Lac-MSNs were cal-
culated as 1335 and 1012 m2/g, 1.85 and 1.33 cm3/g, 4.1
and 3.7 nm, respectively.
Figure 1 Schematic diagram of lactosaminated mesoporous silica nanoparticles.
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ide (CTAB) was used as a mesoporous template for synthe-
sis of MSNs and removed through postsynthesis extraction
with acidic ethanol. Because the marked cytotoxicity of
CTAB was reported by other researchers [36], fourier-
transform infrared spectra (FTIR) analysis was carried out
to confirm the complete removal of CTAB. Typically,Figure 2 SEM images of MSNs (A) and Lac-MSNs (B); TEM images of MCTAB shows two intense peaks at 2800–3200 cm−1, which
correspond to the symmetric (2849 cm−1) and asymmetric
(2918 cm−1) stretching vibrations of the methylene chains
(Figure 5). These peaks were observed in as-synthesized
MSNs but absent in the extracted MSNs, indicating the
complete removal of CTAB through extraction. Moreover,
in FTIR spectra the standard silica, as-synthesized MSNs,SNs (C) and Lac-MSNs (D).
Figure 3 Small-angle XRD patterns of MSNs and Lac-MSNs. Figure 5 FTIR spectra of CTAB, as-synthesized MSNs, extracted
MSNs, and standard silica.
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peaks in the region of 400–1800 cm−1, indicating the MSNs
had the same chemical constituents as the pure silica.
Lactose was conjugated to MSNs through the forma-
tion of Schiff base between the aldehyde group on the
ring-open form of glucose moiety in lactose and the
amino-silane groups in MSNs [28]. Lactose content of
2.11 μg/mg in MSNs was measured by the phenol/sul-
furic acid method, indicating an efficient lactose-binding
on MSNs was achieved.
Targeting efficiency of Lac-MSNs
The cellular uptake of FITC labeled nanoparticles was
studied on two kinds of ASGPR-positive hepatoma cells
HepG2 and SMMC7721, as well as ASGPR-negative fibro-
blast cells NIH 3T3 via laser scanning confocal microscope
(Figure 6). The HepG2 and SMMC7721 cells incubatedFigure 4 Nitrogen adsorption/desorption isotherms of Lac-MSNs
(A) and MSNs (B), with the corresponding pore size distribution
shown in the insert.with Lac-MSNs showed stronger green appearance than
those with MSNs, indicating that lactose modification sig-
nificantly enhanced the cell uptake by ASGPR-positive
cells. However, low cellular uptake by NIH 3T3 cells was
observed for both Lac-MSNs and MSNs, suggesting the
low affinity between ASGPR-negative cells and nanoparti-
cles. Moreover, the cellular internalization of Lac-MSNs by
HepG2 and SMMC7721 cells markedly decreased in the
presence of excess free lactose. This corroborates that
ASGPR on the membrane of hepatoma cells facilitates the
recognition of lactose on Lac-MSNs and increases the cel-
lular uptake through ASGPR-mediated endocytosis.
Flow cytometry was employed to quantitatively evaluate
the cellular internalization of nanoparticles. The logarith-
mic autofluorescence intensity of untreated cells was set
between 100 and 101, and any higher fluorescence intensity
might indicate the cellular internalization of FITC labeled
nanoparticles [2], as the extracellular fluorescence was
already quenched by trypan blue solution [36]. As shown
in Figure 7, the uptake efficiency for Lac-MSNs was 2.1
and 1.8 times higher than that for MSNs in HepG2 and
SMMC7721 cells respectively. Moreover, the presence of
excess free lactose markedly decreased the cellular intern-
alization of Lac-MSNs approximately by 30% and 40% in
HepG2 and SMMC7721 cells, respectively. This further
proved that Lac-MSNs were transported into ASGPR-
positive cells via receptor-mediated endocytosis. Consistent
with the confocal microscope images, both MSNs and Lac-
MSNs showed similar lower cellular uptake efficiency in
ASGPR-negative NIH 3T3 cells.
Therefore, our hypothesis that lactosaminated MSNs
might have a greater ability to actively target the hepa-
toma cells through ASGPR expressed on the cell surface
was proved, and the Lac-MSNs could serve as nanore-
servoirs for targeted drug delivery.
Figure 6 Confocal microscopy images of different cells. ASGPR-positive cells HepG2 (A) and SMMC7721 (B), and ASGPR-negative cells NIH
3T3 (C) incubated with Lac-MSNs (1), MSNs (2), and excess free lactose with Lac-MSNs (3) for 4 h at 37°C. Cell nuclei were stained blue with DAPI,
filamentous actin cytoskeletons were stained red with rhodamine phalloidin, and FITC was shown as green fluorescence.
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Bio-TEM observation on the ultrathin sections of
HepG2 cells after being treated with Lac-MSNs for vary-
ing time was used to explore the process of cellular
uptake and intracellular trafficking. Firstly, a part of Lac-
MSNs were found near the cell membrane, interacting
with the cell surface and inducing the cell membrane
invagination after 10 min of treatment (Figure 8A). Then
the cell membrane pinched off to form endocytic vesicleswhich carried the nanoparticles into the cytoplasm at 1 h
(Figure 8B). After uptake by cancer cells via endocytosis at
4 h, the nanoparticles were processed in endosomes, as
clearly marked by the circle in Figure 8C. The membrane
of endosome surrounding the clumpy nanoparticles finally
broke to release the nanoparticles at 24 h (Figure 8D) [37].
This step is very important, because the drug can only be
released into cytoplasm after the delivery vesicle escapes
from the endosome. Moreover, a large number of MSNs
Figure 7 Flow cytometry study. ASGPR-positive cells HepG2 (A) and SMMC7721 (B), and ASGPR-negative cells NIH 3T3 (C) incubated with
blank medium (control), Lac-MSNs, MSNs, and excess free lactose with Lac-MSNs for 4 h at 37°C. Data represent mean ± SD (n = 3).
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ology, and no nanocarriers were found in the nucleus at
24 h, which is consistent with the literature [38,39].
The influence of incubation temperature on the cellular
uptake of Lac-MSNs was also studied. As shown in
Figure 9, incubation of cells with Lac-MSNs at 4°C signifi-
cantly impeded the uptake, resulting in approximately
90% less uptake than that of control incubated at 37°C.
This indicates that the cellular uptake of Lac-MSNs re-
quires an appropriate temperature, and endocytosis is an
energy-dependent process rather than a passive diffusion.
Furthermore, a series of inhibition experiments were
conducted on HepG2 cells to explore the role of specificFigure 8 Bio-TEM images of HepG2 cells. HepG2 cells treated with Lac-M
the right represent the circled domains on the left with a higher resolutionendocytotic pathways involving in the cellular internaliza-
tion. The influence of various pharmacological inhibitors
on the cellular uptake of Lac-MSNs was also investigated.
Sodium azide, which is widely used as an inhibitor of cel-
lular oxidative respiration, acts by inhibiting cytochrome
C oxidase and thereby blocking the cellular adenosine tri-
phosphate (ATP) synthesis [40]. Chlorpromazine is used
to inhibit the clathrin-mediated endocytosis by inhibiting
the formation of clathrin vesicles. Nystatin binds sterols
and disrupts the formation of caveolae, leading to inhib-
ition of caveolae-mediated endocytosisn [41]. Colchicine is
an inhibitor of non-clathrin non-caveolae-dependent
endocytosis. As shown in Figure 9, the presence of sodiumSNs at 37°C for 10 min (A), 1 h (B), 4 h (C), and 24 h (D). Images on
.
Figure 9 Cellular uptake. Flow cytometry images (A) and quantitative analysis (B) showing the cellular uptake of Lac-MSNs in the presence of
different endocytic inhibitors. Data represent mean ± SD (n = 3). Note: ***p < 0.001 vs control (absence of inhibitor), *p < 0.05 vs control.
Figure 10 In vitro Drug release. Release profiles of DTX from
DTX-MSNs and DTX-Lac-MSNs in PBS at 37°C. Data represent
mean ± SD (n = 3).
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MSNs approximately by 70%, indicating that the uptake is
energy-dependent. Compared with the uptake at 4°C, the
cellular uptake with the presence of sodium azide was ap-
parently higher, which is probably because of the presence
of exogenous ATP and glucose in the media [42]. Simi-
larly, the presence of chlorpromazine and colchicine de-
creased the cellular uptake of Lac-MSNs approximately by
80% and 20% respectively. In contrast, HepG2 cells pre-
treated with nystatin showed negligible reduction in up-
take. Therefore, the results suggested that endocytosis of
Lac-MSNs into HepG2 cells was an energy-dependent
process predominated by clathrin-mediated endocytosis,
and non-clathrin non-caveolae-dependent endocytosis
may represent an additional endocytotic route. This is
consistent with the reported literature [41-43], in which
the endocytosis mechanism of MSNs by A549, KB, and
3T3 cells was investigated.
Drug loading and in vitro release of DTX
One critical challenge for cancer therapy is the limited
availability of effective carriers for most hydrophobic an-
ticancer drugs. In this study, hydrophobic anticancer
drug DTX was successfully loaded into the channels of
MSNs, obtaining drug loading of 10.1 and 12.4 nmol in
1 mg of Lac-MSNs and MSNs respectively as deter-
mined by high performance liquid chromatography
(HPLC). The cumulative DTX release profiles from
DTX-MSNs and DTX-Lac-MSNs in phosphate buffered
saline (PBS) at 37°C are shown in Figure 10. Only 20%
of DTX was released from DTX-Lac-MSNs at 10 h,
showing a slower release rate as compared with DTX-
MSNs. Moreover, it took 96 h for DTX-Lac-MSNs to re-
lease 80% of drug, whereas DTX-MSNs only needed half
of the time. It has been reported that modifying thesurface of mesoporous silica materials could restrict
water diffusing into the matrix and subsequently slow
down the release process [44]. So, the reduced drug re-
lease rate noted for DTX-Lac-MSNs can be explained by
surface modification.
In vitro cytotoxicity of DTX loaded nanoparticles
The biosafety of the drug carriers must be taken into
consideration before application. Herein, MSNs and
Lac-MSNs were incubated with HepG2, SMMC7721,
and NIH 3T3 cells for 72 h at a broad concentration
range of 10–200 μg/ml and their cytotoxicity was evalu-
ated via MTT assay. As shown in Figure 11, both MSNs
and Lac-MSNs showed negligible cytotoxicity in spite of
sample concentration and cell species, as the cell viabil-
ities all remained above 90%.
Figure 11 In vitro cytotoxicity analysis. Viabilities of HepG2 (A), SMMC7721 (B), and NIH 3T3 (C) cells incubated with MSNs and Lac-MSNs for
72 h, and the viabilities of HepG2 (D) and SMMC7721 (E) cells treated with varying concentrations of DTX contained in MSNs and Lac-MSNs for
24 h (1), 48 h (2), and 72 h (3), respectively, at 37°C. Data represent mean ± SD (n = 6).
Table 1 In vitro cytotoxicity of drug loaded nanoparticles
Cells Treatment IC50 (nM)
Time (h) DTX-MSNs DTX-Lac-MSNs
HepG2 24 — —
48 122.43 ± 8.02 51.6 ± 5.51*
72 117.04 ± 20.38 31.55 ± 6.35*
SMMC7721 24 — —
48 72.77 ± 11.14 16.65 ± 3.31*
72 32.61 ± 6.24 10.51 ± 1.01*
IC50 values of DTX-MSNs and DTX-Lac-MSNs against HepG2 and SMMC7721
cells after 24, 48 and 72 h of treatment. Data represent mean ± SD (n = 6).
*Significantly different from DTX-MSNs according to a Student’s t-test and
Mann–Whitney U test (p < 0.05).
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MSNs against both HepG2 and SMMC7721 cells was
measured to assess their specific tumor targeting effect. It
was found the cytotoxicity of DTX-Lac-MSNs and DTX-
MSNs was strongly dependent on the drug concentration
and treatment time. After 48 and 72 h treatment, both
HepG2 and SMMC7721 cells exhibited appreciable level
of cell death. Further calculation was performed to deter-
mine concentrations needed to cause 50% inhibition
(IC50). As shown in Table 1, the IC50 values were much
lower for DTX-Lac-MSNs than for DTX-MSNs against
two kinds of human hepatoma cell lines (p < 0.05). These
results suggested that Lac-MSNs transported DTX into
hepatoma cells more effectively than MSNs, resulting in
distinctly enhanced cytotoxicity, which was correlated to
the aforementioned enhanced cellular uptake. Therefore,
Quan et al. Journal of Nanobiotechnology  (2015) 13:7 Page 9 of 12Lac-MSNs may potentially be used as vehicles for loading
anticancer drugs and targeted cancer therapy.
Conclusions
In summary, a hepatoma targeting drug delivery system
was successfully constructed by conjugation of mesopo-
rous silica nanoparticles with the active targeting agent
lactose. The Lac-MSNs were demonstrated to specifically
target ASGPR-positive HepG2 and SMMC7721 cells, and
their internalization into hepatoma cells is an energy-
consuming process and predominated by clathrin-mediated
endocytosis. Water insoluble anticancer drug DTX was ef-
fectively loaded in the pores of Lac-MSNs, showing signifi-
cantly enhanced cytotoxicity. Therefore, Lac-MSNs provide




Docetaxel (DTX, purity > 99%) was purchased from
Yikangsida Med. Tech. Ltd. (Beijing, China). Lactose mono-
hydrate and sodium cyanoborohydride were obtained from
Aladdin (Shanghai, China). Cetyltrimethyl ammonium brom-
ide (CTAB), tetraethoxysilane (TEOS), (3-aminopropyl)
triethoxysilane (APTES), 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT), 4',6-diamidino-2-
phenylindole (DAPI), phalloidin-tetramethylrhodamine B
isothiocyanate conjugate (rhodamine phalloidin), and fluores-
cein isothiocyanate (FITC) were purchased from Sigma-
Aldrich (St Louis, MO, USA). Propidium iodide (PI) and
Hoechst 33258 were obtained from MP Biomed. (Santa
Ana, USA). Chlorpromazine, nystatin, colchicines, and
sodium azide were obtained from Yuelai Med. Tech. Ltd.
(Xi’an, China). Dulbecco’s modified Eagle’s medium (DMEM),
trypsin-EDTA, fetal bovine serum (FBS), and penicillin-
streptomycin were acquired from GIBCO (Gaithersburg,
MD, USA). All other reagents used were of analytical grade.
Human hepatoma cell lines HepG2 and SMMC7721,
and mouse embryonic fibroblast cell line NIH 3T3 were
obtained from Shanghai Institute of Cell Biology (Chin-
ese Academy of Sciences, Shanghai, China). The cells
were cultured in Dulbecco’s modified eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum
and 100 U/mL of penicillin-streptomycin, and main-
tained at 37°C in a humidified incubator containing 5%




Mesoporous silica nanoparticles were synthesized in al-
kaline media using CTAB as the template and TEOS as
silicon source according to Zink’s report with minor
modification [45]. Briefly, 11 mg of FITC was dissolvedin 6 mL of absolute ethanol and then 24 μL of 3-
aminopropyl triethoxysilane (APTES) was added in. The
solution reacted in the dark for 2 h and then 5 mL of
TEOS was added. In another three-necked flask, 1.0 g of
CTAB and 0.28 g of sodium hydroxide were dissolved
in 480 mL of water, and the resulting mixture was
constantly stirred at 80°C till CTAB was completely
dissolved and the temperature became stable. Subse-
quently, the mixture of TEOS and FITC-APTES was
added dropwise in the flask, and 2 h later, the particles
were collected by centrifugation, washed with water till
the filtrate was neutral, and rinsed twice with alcohol be-
fore dried at 60°C.
Synthesis of lactosaminated MSNs (Lac-MSNs)
Briefly, 1 g of MSNs were dispersed in 150 mL of tolu-
ene, followed by adding 2 mL of NH2-silane (APTES)
and reaction for 4 h at 120°C. Then the obtained parti-
cles were centrifuged, washed with absolute ethanol, and
dried at 60°C. Subsequently, 500 mg of the dried nano-
particles were mixed with 6 mL of lactose solution
(0.34 g/L) and 6 mL of sodium cyanoborohydride solu-
tion (0.31 g/L) sequentially. With gentle shaking several
times daily, the mixture was allowed to react for 7 days.
Finally, the Lac-MSNs were centrifuged, washed with
water to remove the unconjugated lactose, and dried at
60°C. To further remove the template, 500 mg of dry
nanoparticles were redispersed in 100 mL of absolute
ethanol containing 2 mL of concentrated hydrochloric
acid and refluxed for 24 h. Then the particles were col-
lected and washed to remove the template.
Characterization of MSNs
The morphology of MSNs was characterized by SEM
(JSM-6330 F, JEOL, Japan). The samples were sputter-
coated with gold for two cycles prior to imaging. Mesos-
tructure of the nanoparticles was observed by TEM
(JEM-1400, JEOL, Japan) with a drop of dispersed sam-
ple solution being deposited on a carbon-coated copper
grid and dried at room temperature before examination.
The particle size of MSNs was measured at 25°C by
dynamic light scattering at a scattering angle of 90° using
Zetasizer Nano ZS90 (Malvern Instruments, Worcester-
shire, UK). The mesostructure ordering was analyzed
by small-angle X-ray diffraction (SAXRD, D/MAX 2200
VPC, Tokyo, Japan) using Cu Kα radiation with 2θ in
the range of 0.6°-6° at a scanning rate of 0.5°/min.
Brunauer-Emmett-Teller (BET) surface area, pore vol-
ume and diameter distribution of MSNs were measured
at −196°C by using a surface area and pore size analyzer
(ASAP 2020C, Micromeritics, USA). FTIR spectra of
MSNs were obtained by using a FTIR spectrophotometer
(Bruker, German) to scan over a region of 400–4000 cm−1
on a thin KBr slice containing MSNs.
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Lactose content was measured by the phenol/sulfuric acid
method [46]. Since the secondary amine formed between
amino-MSNs and glucosyl by reductive amination is acid-
stable, only galactose is produced during the hydrolysis
[47]. Briefly, 2 mL of standard galactose solution at various
concentrations, 1 mL of phenol (5%), and 4 mL of concen-
trated sulfuric acid were added in a tube. The tube was
sealed and allowed to react for 15 min, and the absorbance
after reaction was measured at 490 nm to build a standard
curve. Then, dispersion of Lac-MSNs (50 mg) in deionized
water (2 mL) was treated similarly, the absorbance was
measured and the lactose content was calculated accord-
ing to the standard curve.
Confocal microscopy study
The cellular uptake of nanoparticles was visualized by
confocal microscopy [36]. HepG2, SMMC7721, and NIH
3T3 cells were seeded at 1 × 105 per dish in special glass
dishes and allowed to attach for 24 h. Then, Lac-MSNs
and MSNs suspensions in DMEM at a final concentra-
tion of 50 μg/mL were added in. After 4 h of incubation,
the medium was removed and the cells were washed
with cold PBS (pH 7.4) three times. Trypan blue PBS so-
lution (0.4%) was added to quench any fluorescence out-
side the cells for 10 min. Afterwards, the cells were fixed
with 4% paraformaldehyde at room temperature for
10 min and extracted with 0.1% Triton X-100 in PBS
for 3 min. Subsequently, the filamentous actin cytoskel-
eton was stained with 200 ng/mL rhodamine phalloidin
for 20 min, followed the nuclei staining with DAPI
for 10 min. Finally, the samples were analyzed with the
laser scanning confocal microscope (LSCM, Zessi LSM
710, Germany).
Flow cytometry study
Cellular uptake was quantitatively analyzed by flow cytom-
etry. HepG2, SMMC7721, and NIH 3T3 cells were seeded
into 12-well plates at the density of 2 × 105 cells per well
and allowed to attach for 24 h. Then, Lac-MSNs and
MSNs suspensions in DMEM at a final concentration of
50 μg/mL were added in for cell incubation. After 4 h of
incubation, the medium was removed and 0.4% trypan
blue PBS solution was added to neutralize the extracellular
fluorescence. Then the cells were harvested by trypsiniza-
tion, collected by centrifugation, and resuspended in 4%
paraformaldehyde PBS solution. Finally, the collected cells
were analyzed by a Beckman Coulter EPICS XL flow cyt-
ometer (Beckman Coulter, Fullerton, CA, USA). The regu-
lar DMEM was applied as the blank control. All the tests
were performed in triplicate.
In order to assess the competitive uptake efficacy, the
cells were preincubated with 50 μg/mL of excessive free
lactose for 30 min at 37°C. Then 50 μg/mL of Lac-MSNswere added for incubation at 37°C for another 4 h. Fol-
lowing the similar procedures above, the fluorescent im-
ages were taken with confocal microscopy and the
quantitative results were measured by flow cytometer.
Cell transmission electron microscopy (TEM)
Bio-TEM observation was performed on ultrathin sec-
tions of HepG2 cells after being treated with Lac-MSNs
to reveal the endocytic process of the nanoparticles into
cancer cells and their intracellular locations [48]. Cells
were seeded into 12-well plates at the density of 2 × 105
cells per well and allowed to attach for 24 h. Then
Lac-MSNs were added in for incubation at 37°C for
10 min, 1 h, 4 h, and 24 h. After that, the cells were har-
vested and centrifuged at 4000 rpm for 1 min, immedi-
ately fixed with 2.5% glutaraldehyde solution in PBS for
at least 1 h, post-fixed with 1% aqueous osmium tetrox-
ide for another hour, dehydrated by ethanol series,
washed three times with acetone, and embedded in Spurr
resin medium overnight. Ultrathin sections of the cells
were obtained by 300 mesh copper grids and contrasted
with 0.3% lead citrate and 50% uranyl acetate. Finally, the
samples were visualized with TEM.
Endocytosis-inhibition experiments
A series of endocytosis-inhibition experiments were per-
formed on HepG2 cells to further investigate the endo-
cytosis mechanism of Lac-MSNs as follows [41,42]. Cells
were cultured in a 12-well plate at the density of 2 × 105
cells per well for 24 h. First, the cells were pretreated
with various endocytosis inhibitors for 30 min, including
chlorpromazine (20 μg/mL) for inhibition of clathrin-
mediated endocytosis, nystatin (30 μg/mL) for inhibition
of caveolae-mediated endocytosis, colchicine (20 μg/mL)
for inhibition of non-clathrin non-caveolae-dependent
endocytosis, and sodium azide (3 mg/mL) for ATP. Then
the medium was replaced with 50 μg/mL Lac-MSNs
suspension. After incubation at 37°C for 4 h, the cells
were harvested and analyzed by flow cytometer. Another
uptake study was performed similarly at 4°C for inhib-
ition of cell respiration to further determine whether
the uptake of Lac-MSNs into human hepatoma cells
was energy-dependent. All the tests were performed in
triplicate.
Drug loading and release study
Model drug DTX was loaded in the pores of the nano-
particles by wetness impregnation method [21]. MSNs
and Lac-MSNs (100 mg each) were added to 5 mL of
ethanol solution containing 5 mg/mL of DTX, respect-
ively. Magnetic stirring was applied at room temperature
for 24 h to maximize drug loading in the pores. Then
the drug-loaded nanoparticles (DTX-MSNs and DTX-
Lac-MSNs) were collected by centrifugation, washed
Quan et al. Journal of Nanobiotechnology  (2015) 13:7 Page 11 of 12twice with PBS to remove the free drug on the particle
surface, and dried under vacuum.
The drug-loaded nanoparticles (10 mg) were resus-
pended in methanol because of the high solubility of
DTX in methanol to determine the amount of drug ac-
tually loaded in the nanoparticles. The suspension was
sonicated to dissolve DTX from the pores, and then
the supernatant was collected by centrifugation. This
process was repeated twice to ensure the loaded drug
was completely removed from the pores. The concentra-
tion of DTX in the supernatant was determined by
HPLC (Daojing, Japan).
Pretreated dialysis bags with dialyzer molecular weight
cutoff 14,000 Da were used in the drug release experi-
ments. DTX-MSNs and DTX-Lac-MSNs samples (20 mg
each) were dispersed in 2 mL of PBS, and the solutions
were placed into the pretreated dialysis bags. The sealed
bags were immersed in 10 mL of PBS and shaken at
100 rpm at 37°C. The release medium was taken and
replaced with fresh medium at given time intervals. Each
release study was performed in triplicate. The concentra-
tion of DTX in samples was measured by HPLC.
Cytotoxicity study
The cytotoxicity of MSNs, Lac-MSNs, DTX, DTX-
MSNs, and DTX-Lac-MSNs was evaluated against
HepG2 and SMMC7721 cells by MTT viability assay.
Cells were seeded in 96-well plates at a density of 5 ×
103 cells per well. After incubation in 5% CO2 at 37°C
for 24 h, the medium was replaced with 200 μL of fresh
medium containing different concentrations of samples.
Cells treated with pure medium were used as the blank
control. After incubation with the samples for 24, 48,
and 72 h, the medium was replaced with 20 μL of MTT
(5 mg/mL) and 180 μL of fresh medium for another 4 h
of incubation at 37°C. Finally, 150 μL of DMSO was
added in each cell to dissolve the purple formazan crys-
tals and the absorbance was measured at 490 nm by an
ELX 800 micro-plate reader. The cytotoxicity was calcu-
lated as the percentage of cell viability as compared with
the blank control, and data were expressed as mean ±
standard deviation (SD) of six independent wells. The
IC50 values of different formulations were calculated via
nonlinear regression of the log(dose)-response profiles
using GraphPad Prism 5.
Statistical analysis
IC50 values of DTX-MSNs and DTX-Lac-MSNs were
compared using the Student’s t-test and Mann–Whitney
U test following normality and equal variance tests
(SPSS 13.0). Statistical analysis of the effects of various
pharmacological inhibitors on the cellular uptake of
Lac-MSNs was performed using a one-way ANOVA
(SPSS 13.0). The post-hoc comparisons of the means ofindividual groups were performed using least significant
difference test. Differences were considered significant
if P < 0.05.
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